Surge in the number of bloodstream infections drives the growth of the global blood stream infection testing market. The market across Asia-Pacific is projected to portray the highest CAGR of 9.2% during the forecast period. The Covid-19 pandemic caused a global public health emergency and negatively impacted the global bloodstream infection testing market share.
The global blood stream infection testing market would reach $5.17 billion by 2021, and would generate $10.54 billion by 2030, growing at a CAGR of 8.3% from 2022 to 2030.
- The Covid-19 pandemic caused the global public health emergency and negatively impacted the global bloodstream infection testing market share.
- However, as blood culture test considered as standard for diagnosis of the infection, the demand for BSI testing increased.
The global blood stream infection testing market is classified on the basis of product, technique, technology, application, end-users, and region.
Based on technology, the culture-based segment dominated the market in terms of revenue in 2021, contributing to around three-fifths of the market. However, the molecular segment is expected to manifest the highest CAGR of 9.2% during the forecast period.
On the basis of product, the instruments segment is estimated to register the highest CAGR of 8.7% during the forecast period. However, the consumables segment held the lion’s share in 2021, accounting for nearly four-fifths of the market.
Based on technique, the automated segment is projected to register the highest CAGR of 9.1% during the forecast period. However, the conventional segment held the largest share in 2021, accounting for more than two-thirds of the market.
On the basis of application, the bacterial segment held the largest share in 2021, contributing to more than half of the market. In addition, the segment is projected to register the highest CAGR of 8.9% during the forecast period.
For Purchase Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/3934
Based on end-users, the independent diagnostics centers segment is estimated to showcase the highest CAGR of 8.8% during the forecast period. However, the hospitals segment held the largest share in 2021, accounting for more than half of the market.
The global blood stream infection testing market is analyzed across several regions such as North America, Europe, Asia-Pacific, and LAMEA. The market across Asia-Pacific is projected to portray the highest CAGR of 9.2% during the forecast period. However, the market across North America would contribute the largest share in 2021, accounting for around two-fifths of the market.
The global blood stream infection testing market includes an in-depth analysis of the prime market players such as Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Abbott, BD, BIOMÉRIEUX, Cepheid, Luminex Corporation, Accelerate Diagnostics Inc., AdvanDX, and Bruker.
The report analyzes these key players in the global blood stream infection testing market. These players have adopted various strategies such as new product launches, expansion, partnerships, and others to increase their market penetration and strengthen their position in the industry. The report is helpful in determining the business performance, operating segments, product portfolio, and developments of every market player.
0 Comments